- Fast-Track assessment of variations (Amendments) and CTD dossier applications
- Unauthorized Chinese Pill Tablets on the Market
- WHO Global alert on substandard (contaminated) pediatric cough syrups identified in Gambia – West Africa
- Implementation of the National Drug Policy and Authority (fees) Regulations 2022
- National Drug Authority statement on conduct of Clinical Trials during the COVID-19 lockdown
- Emergency use of Remdesivir in the context of the Covid-19 Pandemic
- Pharmacovigilance requirements for Remdesivir products under emergency importation
- Requirement for a Pharmacovigilance system for licensed persons in Uganda
- Provisions for emergency importation of Remdesivir in the context of the COVID-19 Pandemic
- Communication circular on Clinical Trial new format for CT certificates
- Adulterated Herbal products on the market
- Caution against stockpiling and irrational use of medicine
- Certification of premises used to supply restricted drugs within institutions conducting clinical trials
- Presence of a potentially genotoxic impurity, N-nitrosodimethylamine (NDMA) in Ranitidine
- Circular on Importation, Exportation & sale of Chloroquine & Hydroxychloroquine
- Increased risk of non-melanoma skin cancer associated with HCTZ
- Clarification on Hydrochlorothiazide
- Furosemide injection manufactured by Grand pharmaceutical (china) co., ltd; batch number 180120
- Disabling and potentially permanent side effects associated with quinolone and fluoroquinolone antibiotics
- Risk of crystalization of Mannitol 20% iv solution
- Recall of Valsartan a drug used in the treatment of high blood pressure
- Gentamycin Injection
- Risk of drug interactions and side effects due to use of herbal remedies – Anticancer Treatment
- Notice to cease purchase and use of Rabicid-iv (Rabeprazole injection ip)
- Risk of hypersensitivity reaction in infants and children following administration of Nevirapine
- Increased risk of otoxicity following concomitant administration of Gentamicin and Furosemide
- Risk of Abortion and birth defects with fluconazole
- Previously unidentified potential risk of visual color distortions with Pregabalin
- Public Alert – Counterfeit Cancer Medicine (Sutent)
- Public Alert – Counterfeit Cancer Medicine (Avastin)
- Drugs disguised as cosmetics
- Public Notice on Anti-Malarial products
- Public notice on LAVA EC
- Public notice on Machupo virus – paracetamol
- Alert on Wallet Pack Counterfeit Coartem
- Falsified AMARIL yellow fever vaccines circulating in South East Asia
- Detection of Impurity in the Active Pharmaceutical Ingredient (API) valsartan manufactured by Zhejiang Huahai Pharmaceuticals, Linhai, China
- Mandatory Post Shipment Circular
- Circular on Unaunthorised Medical Devices on the Ugandan Market
- Mandatory sampling and testing of selected surgical instruments and appliances
- Circular on Importation of Healthcare Products for surgical / medical/ dental camps
- Circular on Implementation of Statutory Instrument No. 82 of 2023
- Adulterated L-power coffee supplied by Liven Global SDN. BHD – Malaysia
- Circular on importation and distribution of Hypodermic Syringes and Needles
- Signposts for drug outlets
- Renewal of licenses
- Annual return of details of pharmacy business
- WHO Global alert on substandard (contaminated) pediatric cough syrups identified in Gambia – West Africa
- Implementation of the National Drug Policy and Authority (fees) Regulations 2022
- Ban on the use Chloroform (Trichloromethane) in Pharmaceutical preparations
- Annual Return of details of pharmacy business
- Labeling Requirements for Medical face masks
- Adulterated M-Magix coffee on the market
- Labelling requirements for surgical sutures
- Guidance on the attributes of a valid proforma invoice when importing unregistered drugs
- Public Warning : Adulterated & substandard herbal products on the market – Embaluka hardcore drink & Megapower
- Analysis for Nitrosamine impurities in drugs
- Circular on falsified chloroquine products circulating in Africa
- Circular on falsified Human Immunodeficiency Virus (HIV) Uni-Gold test kits
- Circular on Importation of personal protective equipment
- Withdraw of marketing authorization for Ketoconazole oral Tablets
- Circular No. 01-DPAR-2024_Submission of Vet Pharma Product Dossiers in CTD Format
- Fast-Track Assessment of CTD Dossier Applications
- Implementation of the National Drug Policy and Authority (fees) Regulations 2022
- Extension of the deadline for submission of CTD dossiers for renewal of registration
- Retention of products for the financial year 2020 / 2021
- Circular no.2 – suspension of registration of products from the drug register
- Circular no.23 – suspension of registration of products from the drug register
